SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

SULANDA

HCM·HUTCHMED (China) Ltd
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (China) and commercially marketed; ongoing Phase 2 academic combination studies elsewhere
Time to market
Already approved and marketed in China (Sulanda); no US/EU filing appears in the active pipeline, and no FDA action or catalyst records exist in the ingested data.
Why 3/10
No hard, dated binary catalyst (no PDUFA, no registrational readout) is scheduled for Sulanda in the next ~12 months, it is an already-approved, commercially marketed drug in China, and HUTCHMED's next binary readouts (SAFFRON/SANOVO Phase III, sovleplenib NDAs) belong to other programs, so it scores at the low end of the approved-with-no-pending-decision band (3).
Actionable Insight NEUTRAL

Sulanda is a commercial revenue contributor, not a binary catalyst: H1 2026 in-market sales grew ~45% to $18.4M, but the next big HCM stock movers (savolitinib SAFFRON/SANOVO Phase III readouts expected H2 2026, two sovleplenib NDA decisions in China) are different drugs. Watch China NRDL/pricing news and NET competition for Sulanda-specific pressure; watch SAFFRON/SANOVO and sovleplenib for the actual share-price catalysts.

Price Chart

Loading chart...

Executive Summary

Sulanda (surufatinib) is HUTCHMED's already-approved, China-marketed oral cancer drug for neuroendocrine tumors; HUTCHMED's H1 2026 interim filing shows Sulanda in-market sales of $18.4M, up ~45% year over year and one of the company's fastest-growing China products (alongside Elunate +41%). It is a small slice of HUTCHMED (a ~$1.99B-market-cap company whose H1 2026 product revenue was $121.4M and cash $1.37B), and the stock's next hard catalysts, savolitinib SAFFRON/SANOVO Phase III readouts in H2 2026 and sovleplenib NDA decisions, belong to other drugs, not Sulanda.

How It Works

Sulanda (surufatinib) is an oral "multikinase inhibitor" pill that blocks several enzymes (VEGFR1/2/3, FGFR1, CSF-1R) involved in building new blood vessels that feed tumors and in suppressing the immune system's attack on cancer. By cutting a tumor's blood supply and easing immune suppression, it slows tumor growth, a strategy used in neuroendocrine tumors (NETs), where it is approved in China.

Trial Status

Marketed product in China with H1 2026 in-market sales of $18.4M (+45% YoY per HUTCHMED's interim-results filing). No registrational (pivotal) trials sponsored by HUTCHMED appear in the ingested pipeline for surufatinib; remaining activity is investigator-sponsored Phase 2 studies (e.g., peri-operative pancreatic cancer combo, completed; pancreatic NET adjuvant, terminated; platinum-resistant ovarian cancer combo, completed), plus updated surufatinib-combination data in GI/pancreatic cancers presented at AACR 2026. No FDA approvals, actions, or catalysts recorded.

The Two-Sided Case

▲ Bull Case4
Already approved and commercialized in China, no development or approval risk remaining; it is generating real revenue today (H1 2026 in-market sales $18.4M, +45% YoY per HUTCHMED's interim-results 6-K analysis).
Sulanda is a growth leader in HUTCHMED's China commercial recovery, alongside Elunate (+41%) and Fruzaqla ex-US (+70%), inside a 23% YoY increase in Oncology/Immunology product revenue to $121.4M.
Ongoing combination studies in GI/pancreatic cancers (updated data presented at AACR 2026 per company press release) add pipeline optionality on top of the commercial base.
Parent company is cash-rich ($1.37B cash per H1 2026 filing) and heavily analyst-favored: 13 buy / 3 hold / 0 sell with a mean price target of $21.77 vs $11.13 price (~77% implied upside), per analyst-consensus data.
▼ Bear Case5
No hard, dated binary catalyst for Sulanda in the next ~12 months, an approved drug with no pending PDUFA/readout can only drive modest, sales-driven moves; the stock's real binaries (SAFFRON/SANOVO Phase III H2 2026, sovleplenib NDAs) are other programs.
Small share of value: $18.4M of H1 2026 in-market sales versus $121.4M total Oncology/Immunology product revenue and a ~$1.99B market cap, even a big Sulanda swing moves HCM only slightly.
China-only commercial footprint with the company's own risk list flagging NET competition from newer therapies and an uncertain NRDL/pricing/payer environment that could pressure margins.
No US regulatory path in the active pipeline, no FDA action or catalyst records exist for this drug in the ingested data, capping ex-China upside.
Institutional footprint among SecBot's tracked 13F managers is minimal (only 3 small tracked holders in 2026-Q2), and no quant-signal snapshot exists for HCM.

Upcoming Catalysts

  • None specific to Sulanda: no PDUFA date or registrational readout scheduled in the data; watch H2 2026 HUTCHMED earnings for Sulanda sales trends and any China combo-trial updates (e.g., GI/pancreatic cancer data).
  • Company-level catalysts to watch instead: SAFFRON and SANOVO Phase III topline readouts expected H2 2026 (savolitinib), and decisions on two sovleplenib NDAs under China priority review.
  • Potential AACR/ASCO-style conference data updates on surufatinib combinations (data-dependent, not dated binary events).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

HUTCHMED (China) Ltd 6-K HCM ·Originating report

Sources · 6

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov6 sec.gov